Hartmut Vatter

Efficacy and safety of minimally invasive surgery with thrombolysis in intracerebral haemorrhage evacuation (MISTIE III): a randomised, controlled, open-label, blinded endpoint phase 3 trial

Daniel F. Hanley, Richard E. Thompson, Michael Rosenblum et al. · The Lancet · 2019 · 850 citations · Full text

Thrombosis, Endpoint Phase 3, Interventional Neuroradiology +12

Intraoperative MRI guidance and extent of resection in glioma surgery: a randomised, controlled trial

Christian Senft, Andrea Bink, Kea Franz et al. · The Lancet Oncology · 2011 · 792 citations

Glioma Surgery, Neuro-oncology, Surgical Oncology +11

Lomustine-temozolomide combination therapy versus standard temozolomide therapy in patients with newly diagnosed glioblastoma with methylated MGMT promoter (CeTeG/NOA–09): a randomised, open-label, phase 3 trial

Ulrich Herrlinger, Theophilos Tzaridis, Frederic Mack et al. · The Lancet · 2019 · 556 citations · Full text

Hematological Malignancy, Neuro-oncology, Treatment Strategies +13

Cranioplasty after Decompressive Craniectomy: The Effect of Timing on Postoperative Complications

Patrick Schuss, Hartmut Vatter, Gerhard Marquardt et al. · Journal of Neurotrauma · 2011 · 211 citations

Surgery, Late Cp, Craniomaxillofacial Trauma +16

Glioblastoma therapy in the elderly and the importance of the extent of resection regardless of age

Ági Oszvald, Erdem Güresir, Matthias Setzer et al. · Journal of neurosurgery · 2011 · 173 citations